Facial Emotion Processing and GABAergic Modulation in Individuals at Clinical High-Risk for Psychosis

Deficits in social cognition, including facial emotion recognition (FER), are present in individuals at clinical high-risk for psychosis (CHR-P). Altered GABAergic and glutamatergic signalling within corticolimbic circuitry has been proposed to underlie FER deficits in psychosis. We investigated FER performance and brain activation in CHR-P individuals, and whether pharmacological enhancement of GABAergic signalling with diazepam modulates these processes. In Study 1, 24 antipsychotic-naive CHR-P individuals and 24 healthy controls underwent fMRI while performing the Penn Emotion Recognition Task. In Study 2, 24 antipsychotic-naive CHR-P individuals participated in a randomised, double-blind, placebo-controlled, crossover study of 5mg diazepam versus placebo. Threat-related FER performance and neural activation were compared between groups and drug conditions. In Study 1, CHR-P individuals showed longer reaction times across emotions (n=22 vs n=23, p=0.01) and greater amygdala (pFWE=0.01) and hippocampal (pFWE=0.04) activation for neutral>fixation. Lower amygdala activation for threat>neutral (pFWE=0.03) and non-threat>neutral (pFWE=0.01), and lower hippocampal activation for non-threat>neutral (pFWE=0.04) may reflect this elevated response to neutral faces. Follow-up analyses showed lower insula (pFWE=0.01) and medial prefrontal cortex activation (pFWE=0.02) for threat>fixation. In Study 2, no significant drug effect on sensitivity was observed in the full sample (n=23), although secondary reduced-sample analyses, excluding one participant identified as influential, suggested improved overall sensitivity under diazepam (n=22; p=0.0499). After adjusting for global cerebral blood flow, diazepam reduced midcingulate cortex activation during neutral>fixation (pFWE=0.04). These findings highlight altered neural processing of neutral expressions in individuals at CHR-P, and suggest that aspects of emotion processing may be sensitive to GABAergic modulation.

Authors

Institutions

Publication Details

Journal
medRxiv
Published
2026-11-16
DOI
https://doi.org/10.64898/2026.11.12.26367443
Primary Topic
Schizophrenia research and treatment
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Facial Emotion Processing and GABAergic Modulation in Individuals at Clinical High-Risk for Psychosis

Philip McGuire, Maria Antonietta Nettis, Nicholas R Livingston, James Davies et al.
medRxiv
Schizophrenia research and treatment
preprint

Facial Emotion Processing and GABAergic Modulation in Individuals at Clinical High-Risk for Psychosis

Philip McGuire, Maria Antonietta Nettis, Nicholas R Livingston, James Davies, Mitul Ashok Mehta, Thomas James Reilly, Cecilia Casetta, Natasha Vorontsova, Amanda Kiemes, Paulina B. Lukow, Matthew B. Wall, Thomas J. Spencer, Anthony Grace, Aikaterini Dima, Nikita Julius, Maria-Mihaela Avram, Andrea; id_orcid 0000-0002-8358-5715 De Micheli, Edward Chesney, Kosha Ruparel, Owen O’Daly, Federico Turkheimer, Samuel R. Knight, Fernando Zelaya, Ruben C Gur, Peter CT Hawkins, Luke Jelen, Steven CR Williams, Paolo Fusar-Poli, Gemma Modinos
preprint en

Abstract

Deficits in social cognition, including facial emotion recognition (FER), are present in individuals at clinical high-risk for psychosis (CHR-P). Altered GABAergic and glutamatergic signalling within corticolimbic circuitry has been proposed to underlie FER deficits in psychosis. We investigated FER performance and brain activation in CHR-P individuals, and whether pharmacological enhancement of GABAergic signalling with diazepam modulates these processes. In Study 1, 24 antipsychotic-naive CHR-P individuals and 24 healthy controls underwent fMRI while performing the Penn Emotion Recognition Task. In Study 2, 24 antipsychotic-naive CHR-P individuals participated in a randomised, double-blind, placebo-controlled, crossover study of 5mg diazepam versus placebo. Threat-related FER performance and neural activation were compared between groups and drug conditions. In Study 1, CHR-P individuals showed longer reaction times across emotions (n=22 vs n=23, p=0.01) and greater amygdala (pFWE=0.01) and hippocampal (pFWE=0.04) activation for neutral>fixation. Lower amygdala activation for threat>neutral (pFWE=0.03) and non-threat>neutral (pFWE=0.01), and lower hippocampal activation for non-threat>neutral (pFWE=0.04) may reflect this elevated response to neutral faces. Follow-up analyses showed lower insula (pFWE=0.01) and medial prefrontal cortex activation (pFWE=0.02) for threat>fixation. In Study 2, no significant drug effect on sensitivity was observed in the full sample (n=23), although secondary reduced-sample analyses, excluding one participant identified as influential, suggested improved overall sensitivity under diazepam (n=22; p=0.0499). After adjusting for global cerebral blood flow, diazepam reduced midcingulate cortex activation during neutral>fixation (pFWE=0.04). These findings highlight altered neural processing of neutral expressions in individuals at CHR-P, and suggest that aspects of emotion processing may be sensitive to GABAergic modulation.

medRxiv
King's College London (GB), Perceptive Engineering (United Kingdom) (GB), University College London (GB), Imperial College London (GB), University of Pennsylvania (US)
Good health and well-being
Schizophrenia research and treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon